Orchid Pharma says EXBLIFEP income runs at $3m-$4m yearly
Key highlights
- Orchid Pharma disclosed an EXBLIFEP royalty and milestone-payment run rate of $3 million to $4 million per year.
- Russia and Latin America licensing opportunities carry estimated 10-year sales of $178 million and $80 million, respectively.
- EXBLIFEP registrations in Russia and Latin America may take 12 to 24 months before supply begins.
- Orchid Pharma reported Q2 FY27 revenue of Rs 341 crore, up 14%, and EBITDA including other income of Rs 52 crore, up 148%.
powered by IRIS

On November 17, 2026, Orchid Pharma Limited said EXBLIFEP royalties and milestone payments were running at $3 million to $4 million annually. The run rate is the company’s first numerical disclosure of licensing-platform income, but it depends on country-specific registration and partner launch steps before signed markets can begin commercial supply.
Know Orchid Pharma inside out
Results, valuation, peers and who's buying, in one view.
What is Orchid Pharma's EXBLIFEP royalty run rate?
Orchid Pharma said the current annual run rate for EXBLIFEP royalties and milestone payments is $3 million to $4 million. Management disclosed the figure during its Q2 FY27 earnings call in response to an analyst seeking greater detail on licensing income, calling it the level expected from the business “right now” rather than a quarterly result or formal earnings target.
The disclosed run rate combines two income streams: royalties associated with licensed commercial activity and milestone payments under licensing agreements. Orchid Pharma did not disclose the amount from either stream separately, identify individual partner contributions, or give geography-wise sales volumes. Management said the European business was still small, although it described its growth trajectory as encouraging.
EXBLIFEP remains in an early commercialisation phase, according to management. Orchid Pharma said it is building the platform market by market, with a contract manufacturing organisation, or CMO, already manufacturing and supplying the product to Europe and the Middle East. For Russia and Latin America, management said manufacturing capacity is not the constraint; country-level registrations must be completed before supply starts.
Where has Orchid Pharma licensed EXBLIFEP?
Orchid Pharma has cited estimated 10-year sales of about $178 million in Russia and $80 million in Latin America for EXBLIFEP licensing agreements. These figures are projected commercial sales over a decade, not reported revenue, royalty income or guaranteed contractual receipts. Management said value in both markets will depend on registration, launch and market development.
The Latin America agreement covers only one part of the region and excludes larger countries including Brazil and Argentina, management said. Orchid Pharma is in advanced discussions on other parts of Latin America and is also discussing potential partnerships in Australia, Southeast Asia, Japan and North Africa. Management said it was hopeful of signing three to four additional licensing agreements over the next two quarters, while stressing that the discussions were not concluded arrangements.
In Europe, commercial sales have started in four of the five large markets referred to on the call, while the United Kingdom has yet to begin sales. Management said the United Kingdom uses a procurement model under which the government guarantees minimum annual quantities at a fixed price. Orchid Pharma said a United Kingdom launch could lift revenue and royalties, but did not give an expected launch date or projected annual value.
Got a follow-up? Ask IRIS
When could Orchid Pharma's licensees begin EXBLIFEP sales?
Orchid Pharma said registrations in Russia and Latin America could take 12 to 24 months depending on the country, after which supply would begin. Management expects some Latin American and Southeast Asian countries to progress faster because United States and European registrations can support local registration timelines. Japan and Brazil may take longer because of their regulatory processes.
Management said that two years from November 2026, significantly more markets should have commercial sales and product availability should increase globally. That is a management expectation, not a sales forecast, and remains conditional on partners completing registration and launch processes. Orchid Pharma did not provide a market-by-market calendar, volume estimate or royalty-rate disclosure for signed agreements.
Launches in the Middle East and South Africa had been delayed by regional disruption and were expected by Q1 2027. Management said these markets were already supplied through the CMO model, unlike Russia and Latin America, where commercial supply remains conditional on local registrations. The differing timelines mean signed deals may not begin contributing to royalties simultaneously.
The United States is not among Orchid Pharma's advanced EXBLIFEP discussions. Management described United States discussions as preliminary and gave no timetable for a deal, clarifying that its expectation of covering most of the world within 12 months did not represent a United States signing deadline. Any contribution from that market therefore remains unresolved.
How does EXBLIFEP fit Orchid Pharma's FY27 performance?
EXBLIFEP income is emerging alongside improved reported operating performance in Q2 FY27. Orchid Pharma's revenue from operations increased 14% year on year to Rs 341 crore from Rs 299 crore, while earnings before interest, tax, depreciation and amortisation, or EBITDA, including other income rose 148% to Rs 52 crore from Rs 21 crore. Management said gross margin rose to about 39% from 31%, helped by inventory normalisation, better volumes and product mix.
The Q2 result included an expected credit-loss provision of about Rs 5 crore and a merger-related impairment of about Rs 5 crore, both described by management as one-time accounting items. An analyst said EBITDA excluding other income was about Rs 24 crore and asked whether adding back the two items produced adjusted EBITDA of about Rs 34 crore; management confirmed that interpretation. Profit after tax was Rs 28.6 crore, compared with a Rs 90 lakh loss in Q2 FY26.
For H1 FY27, revenue increased 15% to Rs 645 crore from Rs 562 crore and EBITDA rose to Rs 77 crore from Rs 31 crore. Operating cash flow was about Rs 118 crore, while working-capital utilisation declined to Rs 412 crore at September 2026 from Rs 464 crore in March 2026. These broader figures do not isolate EXBLIFEP income, and management said margins remain sensitive to product mix and market conditions.
Conclusion
Orchid Pharma has established a numerical reference point for its EXBLIFEP licensing platform, with royalties and milestone payments running at $3 million to $4 million annually. The $178 million estimated 10-year Russia opportunity and $80 million Latin America opportunity show the commercial scope management sees, but those figures remain potential sales estimates rather than recognised royalty income.
The next disclosures to watch are the three to four additional licensing agreements management hopes to sign over the next two quarters, Q1 2027 launches expected in the Middle East and South Africa, and registration progress in Russia and Latin America, which may take 12 to 24 months. The United Kingdom procurement start and the absence of a timetable for a United States agreement will also affect the pace of broader commercial sales.


